# Vermedx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vermedx

- Industry: Healthcare IT
- Headquarters: Burlington, US
- Website: www.patientengagementsystems.com
- Total disclosed funding: $1.3M
- Latest round: Series C (Oct 15, 2010)
- Investors on record: 1

## About

Vermedx Inc. specializes in patient engagement solutions that enhance healthcare outcomes and operational efficiency for individuals with chronic conditions, utilizing advanced technology for better patient provider communication and management.Founded in 2006 by Charles MacLean in Burlington, US, Vermedx Inc. focuses on providing patient engagement solutions tailored to healthcare providers. The company has participated in 7 deals, with the most recent funding round occurring on May 28, 2015, during which it raised USD 0.25 mn.Vermedx Inc. offers patient engagement solutions designed to improve healthcare outcomes for those with chronic diseases. Their services facilitate clinical and financial objectives through electronic health records, population health solutions, and laboratory information systems, ultimately aiming to bolster patient compliance and strengthen healthcare relationships. The primary clientele includes healthcare providers, health plans, and clinical sites across the United States, as well as in regions undergoing healthcare reforms internationally.The company generates revenue through subscription-based models alongside partnerships with various healthcare organizations. Clients pay for services based on usage, which includes tools for chronic condition management and patient engagement resources. This enables tailored solutions for healthcare providers, including hospitals and insurance companies, to enhance patient care while ensuring compliance with regulatory standards.Vermedx Inc. is focused on the development of new patient engagement solutions aimed at improving chronic disease management, with plans to roll out these innovations within the next year. The company is also looking to expand its services into international markets, particularly targeting regions experiencing significant healthcare transitions by 2025. Funding raised in May 2015, totaling USD 0.25 mn, will be directed towards these product enhancements and market expansion initiatives.

## Funding rounds

- Series C, Oct 15, 2010, $0.8M — FreshTracks Capital
- Series A, May 1, 2009, $0.5M — FreshTracks Capital

## Investors

- FreshTracks Capital (https://capitalatlas.ai/funds/freshtracks-capital) — Series A, Series C